Proximal Splenic Artery Embolization to Treat Refractory Ascites in a Patient With Cirrhosis
Authors: Cristian Caporali, Laura Turco, Francesco Prampolini, Pietro Quaretti, Marcello Bianchini, Dario Saltini, Francesca Miceli, Federico Casari, Davide Felaco, Juan Carlos Garcia‐Pagan, Jonel Trebicka, Marco Senzolo, Gian Piero Guerrini, Fabrizio Di Benedetto, Pietro Torricelli, Erica Villa, Filippo Schepis
Journal: Hepatology (2021)

Since the early 1970s several studies have reported distal splenic artery embolization, better known as partial spleen embolization (PSE), as an efficacious treatment of portal hypertensive variceal bleeding and hypersplenism in cirrhosis.(1, 2) However, the effect of PSE on portal pressure is secondary to the induction of splenic infarction. Depending on both the infarct volume and possible infection, PSE can induce serious complications including death.(2, 3) On the other hand, proximal splenic artery embolization (PSAE), which mimics surgical splenic artery ligation, prevents large infarction of the spleen, favoring collateral perfusion of its intact distal vasculature.(3) For this, PSAE has been extensively preferred over PSE for reducing portal hyperflow and treating refractory ascites (RA) after whole or partial liver transplantation (LT).(3, 4) We report here a case of PSAE used to treat RA in a patient with cirrhosis not eligible for transjugular intrahepatic portosystemic shunt (TIPS) and LT. A 72-year-old man under regular follow-up at our unit since 2009 (obesity as the main comorbidity, teetotaler, under 80 mg propranolol since 2013 for secondary prophylaxis of variceal bleeding, HCV eradicated in 2016) in October 2018 was admitted for his second acute decompensation (grade 3 ascites, grade 3 hepatic encephalopathy (HE), stage 2 acute kidney injury, no infections). After discharge, despite halving the dose of propranolol, administering 40 g/week of albumin, and tuning the diuretic dosage, grade 3 ascites kept recurring (20 L per month). In February 2019, diuretics were definitively withdrawn for induced complications (renal failure, severe hyponatremia, HE). The patient was judged not eligible for LT, mainly for exceeding the age limit. TIPS was considered not feasible because of the risk of complications related to the patient's age, history of recurrent episodes of HE, and creatinine levels often exceeding 3 mg/dL. At volumetric MRI, the spleen/liver volume ratio (SLVR) was 1.4.(4, 5) After obtaining the patient's consent, we decided to perform PSAE to treat RA following the hypothesis that it would primarily decrease portal pressure and ascites filtration and secondarily lessen the prerenal component of kidney failure. PSAE was performed as described.(3, 4) Pre-PSAE and post-PSAE imaging is shown in Fig. 1. Main clinical, laboratory, hemodynamic, and volumetric features recorded during the main follow-up time points are summarized in Fig. 2. No immediate or late complications related to PSAE were observed. Portal pressure significantly decreased, response/tolerance to diuretic was restored, and 3 weeks post-PSAE ascites disappeared. At the end of follow-up (15 months), estimated glomerular filtration rate improved by 104% and cardiac index and left ventricle stroke work index returned to predecompensation levels. MRI showed an expected reduction in the spleen volume and an unexpected increase in the total liver volume compared to pre-PSAE. Liver function tests, body mass index, and hemoglobin level returned to their predecompensation values. PSAE caused a decrease in portal pressure and ascites filtration. After this, renal response/tolerance to diuretics improved. Decrease in systemic inflammation, normalization of hemoglobin level, and nutritional status recovery may have contributed to renal and cardiac function improvement. The mechanism underlying liver enlargement remains unexplained. Future studies should clarify if it is due to liver regeneration triggered by changes in liver perfusion. Vascular plugs may present technical advantages compared with coils, allowing reliable deployment in a short proximal segment of the splenic artery.(4) The ideal SLVR as a predictor of significant portal pressure reduction after PSAE remains to be determined.(4, 5) In conclusion, the safety and long-term efficacy of PSAE as a therapeutic option in patients with cirrhosis and RA not eligible for TIPS or LT should be tested in larger case series. We thank the patient and his family for trusting us. We also thank the nurses who gracefully supported our work. All authors read and approved the final manuscript. C.C. was responsible for study concept and execution of the procedure. L.T. was responsible for acquisition of hemodynamic data, manuscript drafting, and technical and material support. F.P. was responsible for acquisition of volumetric data and technical and material support. P.Q. was responsible for study concept and critical revision of the manuscript for important intellectual content. M.B. was responsible for acquisition of hemodynamic data and technical and material support. D.S. was responsible for acquisition of clinical data and technical and material support. F.M. was responsible for technical and material support. F.C. and D.F. were responsible for execution of the procedure and technical and material support. J.C.G.-P., J.T., M.S., G.P.G., and F.D.B were responsible for interpretation of data and critical revision of the manuscript for important intellectual content. P.T. and E.V. were responsible for critical revision of the manuscript for important intellectual content. F.S. was responsible for study concept and design, execution of the procedure, acquisition of hemodynamic data, study supervision, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content.